Related Experiment Video
Updated: Apr 25, 2026
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma
Zofia Felicja Bielecka1, Anna Małgorzata Czarnecka2, Cezary Szczylik2
1Department of Oncology with the Laboratory of Molecular Oncology, Military Institute of Medicine , Warsaw , Poland ; Postgraduate School of Molecular Medicine, Medical University of Warsaw , Warsaw , Poland.
Abstract:
Drug resistance mechanisms in renal cell carcinoma (RCC) still remain elusive. Although most patients initially respond to targeted therapy, acquired resistance can still develop eventually. Most of the patients suffer from intrinsic (genetic) resistance as well, suggesting that there is substantial need to broaden our knowledge in the field of RCC genetics. As molecular abnormalities occur for various reasons, ranging from single nucleotide polymorphisms to large chromosomal defects, conducting whole-genome association studies using high-throughput techniques seems inevitable. In principle, data obtained via genome-wide research should be continued and performed on a large scale for the purposes of drug development and identification of biological pathways underlying cancerogenesis. Genetic alterations are mostly unique for each histological RCC subtype. According to recently published data, RCC is a highly heterogeneous tumor. In this paper, the authors discuss the following: (1) current state-of-the-art knowledge on the potential biomarkers of RCC subtypes; (2) significant obstacles encountered in the translational research on RCC; and (3) recent molecular findings that may have a crucial impact on future therapeutic approaches.
Insights
Understanding drug resistance in renal cell carcinoma (RCC) is crucial. This study explores RCC genetics, highlighting the need for large-scale genomic research to overcome resistance and improve targeted therapies.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Drug resistance mechanisms in renal cell carcinoma (RCC) are not fully understood.
- Most patients develop acquired resistance to targeted therapies, and many have intrinsic genetic resistance.
- There is a significant need to advance the understanding of RCC genetics.
Purpose of the Study:
- To review current knowledge on RCC subtype biomarkers.
- To identify challenges in RCC translational research.
- To discuss recent molecular findings impacting future RCC therapies.
Main Methods:
- Review of current literature on renal cell carcinoma (RCC) genetics and targeted therapy resistance.
- Analysis of molecular abnormalities, from single nucleotide polymorphisms to chromosomal defects.
- Emphasis on the necessity of large-scale, high-throughput genome-wide association studies.
Main Results:
- Renal cell carcinoma (RCC) is a highly heterogeneous tumor with unique genetic alterations across histological subtypes.
- Current knowledge on potential biomarkers for RCC subtypes is discussed.
- Obstacles in translational research and recent molecular findings with therapeutic implications are highlighted.
Conclusions:
- Advancing the understanding of RCC genetics is essential for developing effective treatments.
- Large-scale genomic studies are critical for drug development and identifying cancerogenesis pathways.
- Recent molecular discoveries hold promise for improving future therapeutic strategies in renal cell carcinoma.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Pharmacogenomics: Identification of New Drug Targets
02:18Cancer
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase